

Resource Summary Report

Generated by ASWG on Aug 15, 2026

CD44-PE-Vio770, human

RRID:AB_2661028

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-099-143, RRID:AB_2661028

Antibody Information

URL: http://antibodyregistry.org/AB_2661028

Proper Citation: Miltenyi Biotec Cat# 130-099-143, RRID:AB_2661028

Target Antigen: CD44

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution bone marrow, cancer stem cells, CNS cells, endothelial cells, epithelial cells, kidney, leukocytes, lymphocytes, mesenchymal stem cells, myeloid cells, plasma cells, ES and iPS cells, red blood cells, skeletal muscle, skin, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-336. (RRID:AB_2726112).

Antibody Name: CD44-PE-Vio770, human

Description: This monoclonal targets CD44

Target Organism: non-human primate, human

Clone ID: DB105

Antibody ID: AB_2661028

Vendor: Miltenyi Biotec

Catalog Number: 130-099-143

Record Creation Time: 20250820T002142+0000

Ratings and Alerts

No rating or validation information has been found for CD44-PE-Vio770, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution bone marrow, cancer stem cells, CNS cells, endothelial cells, epithelial cells, kidney, leukocytes, lymphocytes, mesenchymal stem cells, myeloid cells, plasma cells, ES and iPS cells, red blood cells, skeletal muscle, skin, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-336. (RRID:AB_2726112).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We have not found any literature mentions for this resource.